Hot Stocks
| ShowHide Related Items >><< - 07/20/20
- S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices
- 07/20/20
- First Hawaiian to replace Emergent BioSolutions in S&P 600 at open on 7/24
- 04/24/20
- First Hawaiian suspends stock repurchase program
EBS Emergent BioSolutions - 07/24/20
- Emergent BioSolutions to replace Caesars in S&P 400 at open on 7/24
- 07/21/20
- Emergent BioSolutions falls -9.6%
- 07/21/20
- Emergent BioSolutions falls -8.7%
- 07/21/20
- Emergent BioSolutions falls -8.4%
- 07/07/20
- Fly Intel: Top five analyst downgrades
- 07/07/20 Wells Fargo
- First Hawaiian downgraded to Underweight from Equal Weight at Wells Fargo
- 07/07/20 Wells Fargo
- First Hawaiian downgraded to Underweight from Equal Weight at Wells Fargo
- 06/29/20 UBS
- First Hawaiian downgraded to Sell from Neutral at UBS
EBS Emergent BioSolutions - 07/17/20 Cantor Fitzgerald
- Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
- 07/02/20 Wells Fargo
- Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
- 06/26/20 Raymond James
- Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
- 06/08/20 Guggenheim
- Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
- 04/24/20
- First Hawaiian reports Q1 EPS 30c, consensus 38c
- 01/28/20
- First Hawaiian reports Q4 adj. EPS 54c, consensus 51c
EBS Emergent BioSolutions - 04/30/20
- Emergent BioSolutions reports Q1 EPS (1c), consensus 1c
- 02/20/20
- Emergent BioSolutions sees FY20 revenue $1.175B-$1.275B, consensus $1.23B
- 02/20/20
- Emergent BioSolutions sees Q1 revenue $190M-$215M, consensus $262.06M
- 02/20/20
- Emergent BioSolutions reports Q4 EPS $1.57, consensus $1.73
- 07/20/20
- Fly Intel: After-Hours Movers
EBS Emergent BioSolutions - 06/08/20
- Fly Intel: Wall Street's top stories for Monday
- 06/08/20
- Fly Intel: Wall Street's top stories at midday
- 04/27/20
- Fly Insider: Accelerate Diagnostics, Abbott among week's notable insider trades
- 04/23/20
- Fly Intel: After-Hours Movers
|
On The Fly
|
Check out this evening's… ShowHide Related Items >><< XENE Xenon Pharmaceuticals - 03/31/20
- Xenon Pharmaceuticals expects cash to fund operations into 2022
- 03/31/20
- Xenon Pharmaceuticals says no change to previous guidance on FX301
- 03/31/20
- Xenon Pharmaceuticals says no change to previous guidance on NBI-921352
- 03/31/20
- Xenon Pharmaceuticals expects results from Phase 2 study of XEN007 in 2020
- 07/08/20
- Triumph subsidiary acquires assets of Transport Financial Solutions
- 03/26/20
- Triumph Bancorp nominates Debra Bradford, Laura Easly to board of directors
PIRS Pieris Pharmaceuticals - 07/20/20
- Pieris phase 1 studies of PRS-343 placed on partial clinical hold by FDA
- 03/23/20
- Pieris Pharmaceuticals provides update on Servier collaboration
- 01/27/20
- Pieris Pharmaceuticals drops 10% after ASKA opts not to exercise PRS-080 option
- 07/20/20
- New Age Beverages jumps 114% after pact to create '$500M enterprise'
- 07/20/20
- New Age to combine with ARIIX, additional E-commerce/direct selling firms
- 03/27/20
- New Age Beverages tweets new Nestea drinks now available at some Costco stores
- 03/26/20
- New Age Beverages announces expansion, donations of immune-system products
- 07/16/20
- Kiniksa receives Orphan Drug designation for rilonacept for pericarditis
- 06/29/20
- Kiniksa says Phase 3 trial of rilonacept meets efficacy endpoints
- 06/17/20
- Kiniksa announces publication of clinical outcomes with mavrilimumab in COVID-19
- 06/16/20
- Consonance Capital Management reports 11% passive stake in Kiniksa
- $126.42 /
+1.275 (+1.02%) - 07/20/20
- IBM says dealing with a weaker dollar
- 07/20/20
- IBM says still not providing guidance for 2020
- 07/20/20
- IBM 'not immune' to macroeconomic environment
- 07/20/20
- IBM says has renewed focus to 'do more' in terms of CSR
- 07/20/20
- Histogen announces common stock purchase agreement with Lincoln Park Capital
- 07/14/20
- Histogen completes patient enrollment for HST 001 Phase 1b/2a trial
- 06/03/20
- Histogen says enrollment underway in Phase 1b/2a trial of HST 001
- 06/01/20
- Histogen doses first patient in Phase 1b/2a trial of HST 001
- 07/20/20
- Hibbett Sports jumps 30% after forecasting Q2 total SSS up in excess of 70% y/y
- 07/20/20
- Hibbett Sports not providing FY21 outlook at this time
- 07/20/20
- Hibbett Sports: Sales results 'exceptional' at this point in the quarter
- 07/20/20
- Hibbett Sports sees 1H total SSS up approximately 20% y/y
- 07/20/20
- S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices
- 07/20/20
- First Hawaiian to replace Emergent BioSolutions in S&P 600 at open on 7/24
- 04/24/20
- First Hawaiian suspends stock repurchase program
- 04/24/20
- First Financial names James Gordon as CFO, succeeding J. Bruce Hildebrand
- 01/21/20
- Fly Intel: After Hours Movers
- 01/21/20
- FB Financial announces merger with Franklin Financial Network
- 06/24/20
- CytoSorbents launches CytoSorb in nine Latin American countries
- 06/09/20
- CytoSorbents awarded $2.9M contract by U.S. Defense Health Agency
- 05/12/20
- CytoSorbents: CytoSorb is E.U. approved to remove rivaroxaban
- 05/05/20
- CytoSorbents expects Q2 products sales to exceed Q1
- 06/15/20
- Cadence teams with TSMC, Microsoft to reduce chip design signoff schedules
- 02/13/20
- Cadence Design acquires Integrand Software, terms not disclosed
- 02/12/20
- Fly Intel: After Hours Movers
- 01/23/20
- TowerJazz, Cadence Design, Kyiv Polytechnic opening new analog design lab
- 07/20/20
- Crown Holdings falls 7% to $64.61 after Q2 results, Q3, FY20 guidance
- 07/20/20
- Crown Holdings to add additional production lines to certain plants in 2021
- 07/20/20
- Crown Holdings CEO says Q2 performance 'solid'
- 05/15/20
- Einhorn's Greenlight adds Altria, exits GM, DXC in Q1
- 07/20/20
- Acadia Phase 3 CLARITY study misses primary endpoint
- 07/20/20
- Acadia says FDA accepts sNDA filing for nuplazid
- 07/20/20
- Acadia: Phase 3 CLARITY study did not achieve statistical significance
- 06/15/20
- Acadia submits Nuplazid sNDA to FDA
- 07/10/20
- Fly Intel: Top five analyst upgrades
- 07/10/20 DA Davidson
- Triumph Bancorp upgraded to Buy from Neutral at DA Davidson
- 07/10/20 DA Davidson
- Triumph Bancorp upgraded to Buy from Neutral at DA Davidson
- 06/02/20 Wells Fargo
- Triumph Bancorp downgraded to Underweight at Wells Fargo on valuation
- $126.42 /
+1.275 (+1.02%) - 07/08/20 Stifel
- IBM consensus for second half, 2021 appears 'reasonable,' says Stifel
- 06/09/20 DA Davidson
- DA Davidson says Cloudera sale 'increasingly likely,' IBM seen as possible buyer
- 04/21/20 Morgan Stanley
- Krishna years away from returning IBM to sustainable growth, says Morgan Stanley
- 04/21/20 Wedbush
- IBM price target lowered to $140 from $155 at Wedbush
- 07/16/20 DA Davidson
- Cadence Design price target raised to $115 from $90 at DA Davidson
- 07/14/20 Wells Fargo
- Cadence Design price target raised to $110 from $100 at Wells Fargo
- 06/15/20 RBC Capital
- Cadence Design price target raised to $101 from $85 at RBC Capital
- 05/28/20 Wells Fargo
- Cadence Design price target raised to $100 from $87 at Wells Fargo
- 01/02/20 Truist
- SunTrust raises price targets on select regional banks on improved margins
- 12/09/19 Sandler O'Neill
- FB Financial downgraded to Hold from Buy at Sandler O'Neill
- 10/23/19 Raymond James
- FB Financial downgraded to Market Perform on valuation at Raymond James
- 10/23/19 Raymond James
- FB Financial downgraded to Market Perform from Outperform at Raymond James
- 04/14/20 Alliance Global Partners
- New Age Beverages at Alliance Global Partners
- 03/11/20 Compass Point
- New Age Beverages price target lowered to $4 from $9 at Compass Point
- 07/22/19 Northland
- Northland downgrades New Age Beverages on 'more realistic' estimates
- 07/22/19 Northland
- New Age Beverages downgraded to Market Perform from Outperform at Northland
- 07/10/20 Susquehanna
- Hibbett Sports price target raised to $30 from $25 at Susquehanna
- 07/10/20 Susquehanna
- Foot Locker upgraded to Positive from Neutral at Susquehanna
- 07/02/20
- Fly Intel: Top five analyst upgrades
- 07/02/20 BofA
- BofA double upgrades Hibbett Sports on COVID market share gains
PBIB Ticker changed to LMST XENE Xenon Pharmaceuticals - 07/20/20 Needham
- Xenon Pharmaceuticals initiated with a Buy at Needham
- 06/01/20
- Fly Intel: Top five analyst initiations
- 05/31/20 Jefferies
- Xenon Pharmaceuticals assumed with a Buy at Jefferies
- 03/25/20
- Fly Intel: Top five analyst initiations
- 07/07/20
- Fly Intel: Top five analyst downgrades
- 07/07/20 Wells Fargo
- First Hawaiian downgraded to Underweight from Equal Weight at Wells Fargo
- 07/07/20 Wells Fargo
- First Hawaiian downgraded to Underweight from Equal Weight at Wells Fargo
- 06/29/20 UBS
- First Hawaiian downgraded to Sell from Neutral at UBS
- 07/15/20 Jefferies
- Canpack's new Scranton plant 'modest negative' for Ball, Crown, says Jefferies
- 07/15/20 Citi
- Can-Pack entry to U.S. would be negative for Ball, Crown, says Citi
- 07/13/20 Jefferies
- Ball Corp. assumed with a Hold at Jefferies
- 07/13/20 Jefferies
- Crown Holdings assumed with a Buy at Jefferies
- 07/16/20 JPMorgan
- JPMorgan boosts Acadia target to $66, likes setup into depression data
- 07/13/20 Oppenheimer
- Relmada Therapeutics initiated with an Outperform at Oppenheimer
- 07/09/20 RBC Capital
- Acadia price target raised to $61 from $58 at RBC Capital
- 07/07/20
- Fly Intel: Top five analyst upgrades
PIRS Pieris Pharmaceuticals - 03/13/20 Baird
- Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
- 03/13/20 Baird
- Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
- 03/12/20 H.C. Wainwright
- Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
- 01/27/20 H.C. Wainwright
- Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
- 06/02/20 B. Riley Securities
- CytoSorbents gaining relevance as COVID-19 treatment, says B. Riley FBR
- 05/14/20 B. Riley Securities
- CytoSorbents label expansion could significantly expand use, says B. Riley FBR
- 05/06/20 B. Riley Securities
- B. Riley boosts CytoSorbents target, says Portola deal highlights value
- 03/25/20 Dawson James
- CytoSorbents being used for COVID-19 in Italy, China, says Dawson James
- 07/17/20 JPMorgan
- Kiniksa risk/reward attractive into Phase 2 data, says JPMorgan
- 06/29/20 Goldman Sachs
- Kiniksa price target raised to $33 from $29 at Goldman Sachs
- 06/29/20 Wedbush
- Kiniksa price target raised to $38 from $30 at Wedbush
- 04/01/20
- Fly Intel: Top five analyst initiations
XENE Xenon Pharmaceuticals - 05/21/20
- Xenon Pharmaceuticals reports Q1 EPS (22c), consensus (32c)
- 07/20/20
- Triumph Bancorp reports Q2 EPS 25c, consensus 7c
- 04/20/20
- Triumph Bancorp reports Q1 EPS (18c), consensus 28c
- 01/21/20
- Triumph Bancorp reports Q4 EPS 66c, consensus 61c
PIRS Pieris Pharmaceuticals - 05/11/20
- Pieris Pharmaceuticals reports Q1 EPS (7c), consensus (17c)
- 04/14/20
- New Age Beverages sees Q1 revenue $62M-$64M, consensus $56.62M
- 03/16/20
- New Age Beverages reports Q4 EPS (83c) with charge, consensus (8c)
- 04/28/20
- Kiniksa expects cash reserves to fund operating plan into 2H21
- 04/28/20
- Kiniksa reports Q4 EPS (48c), consensus (63c)
- 02/26/20
- Kiniksa reports Q4 EPS (58c), consensus (62c)
- $126.42 /
+1.275 (+1.02%) - 07/20/20
- IBM says 'prudent' management enabled it to expand gross profit margin
- 07/20/20
- IBM reports Q2 cloud & cognitive revenue $5.7B, up 3%
- 07/20/20
- IBM reports Q2 adjusted EPS $2.18, consensus $2.07
- 07/20/20
- Notable companies reporting after market close
- 05/26/20
- Hibbett Sports reports Q1 adjusted EPS 31c, consensus 65c
- 03/20/20
- Hibbett Sports says not providing FY21 guidance due to COVID-19 impact
- 03/20/20
- Hibbett Sports reports Q4 adjusted EPS 51c, consensus 62c
- 04/24/20
- First Hawaiian reports Q1 EPS 30c, consensus 38c
- 01/28/20
- First Hawaiian reports Q4 adj. EPS 54c, consensus 51c
- 07/20/20
- FB Financial reports Q2 adjusted EPS 74c, consensus 48c
- 04/27/20
- FB Financial reports Q1 EPS 2c, may not compare to consensus 55c
- 01/21/20
- FB Financial reports Q4 adjusted EPS 70c, consensus 66c
- 07/20/20
- CytoSorbents sees Q2 revenue approximately $9.8M, consensus $9.25M
- 05/05/20
- CytoSorbents reports Q1 EPS (10c), consensus (13c)
- 03/05/20
- CytoSorbents reports FY19 EPS (60c), consensus (64c)
- 03/05/20
- CytoSorbents reports Q4 revenue $7.4M, consensus $6.8M
- 07/20/20
- Cadence Design sees FY20 adjusted EPS $2.50-$2.56, consensus $2.46
- 07/20/20
- Cadence Design sees Q3 adjusted EPS 59c-61c, consensus 63c
- 07/20/20
- Cadence Design reports Q2 adjusted EPS 66c, consensus 52c
- 07/20/20
- Crown Holdings sees FY20 adjusted EPS $5.10-$5.25, consensus $5.00
- 07/20/20
- Crown Holdings sees Q3 adjusted EPS $1.50-$1.60, consensus $1.53
- 07/20/20
- Crown Holdings reports Q2 adjusted EPS $1.33, consensus $1.30
- 04/20/20
- Crown Holdings withdraws 2020 guidance
- 05/07/20
- Acadia cuts FY20 NUPLAZID sales view to $420M-$450M
- 05/07/20
- Acadia Pharmaceuticals reports Q1 EPS (57c), consensus (48c)
- 02/26/20
- Acadia reports Q4 EPS (34c), consensus (36c)
|
Hot Stocks
|
Emergent BioSolutions… Emergent BioSolutions (EBS) will replace Caesars Entertainment (CZR) in the S&P MidCap 400, and First Hawaiian (FHB) will replace Emergent BioSolutions in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 24. S&P MidCap 400 constituent Eldorado Resorts (ERI) acquired Caesars Entertainment in a deal completed July 20. Post-merger, Eldorado Resorts will change its name to Caesars Entertainment and its ticker to CZR. It will remain in the S&P MidCap 400. ShowHide Related Items >><< - 04/24/20
- First Hawaiian suspends stock repurchase program
- 07/13/20
- Eldorado Resorts gets Indiana HRC approval for Caesars deal
EBS Emergent BioSolutions - 07/20/20
- First Hawaiian to replace Emergent BioSolutions in S&P 600 at open on 7/24
- 07/20/20
- Emergent BioSolutions to replace Caesars in S&P 400 at open on 7/24
- 07/08/20
- Emergent BioSolutions enters collaboration with two others to evaluate COVID-HIG
- 07/06/20
- Emergent enters five-year agreement with Janssen for Ad26.COV2-S manufacturing
- 07/20/20
- Caesars, Eldorado Resorts announced completion of merger
- 07/17/20
- Eldorado Resorts secures NJ CCC approval in connection with Caesars deal
- 07/15/20
- Caesars reports reopening performance for Regional and Destination properties
EBS Emergent BioSolutions - 07/17/20 Cantor Fitzgerald
- Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
- 07/02/20 Wells Fargo
- Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
- 06/26/20 Raymond James
- Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
- 06/08/20 Guggenheim
- Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
- 07/08/20 Jefferies
- Eldorado Resorts price target raised to $51 from $38 at Jefferies
- 06/29/20 Stifel
- Stifel boosts Eldorado Resorts target to $60, sees 'triple-digit stock' soon
- 06/04/20 Deutsche Bank
- Caesars price target raised to $12 from $11 at Deutsche Bank
- 06/02/20 Nomura
- Eldorado Resorts price target raised to $34 from $12.50 at Nomura Instinet
- 06/12/20 Truist
- SunTrust raises price target on select Gaming names amid positive room-rate data
- 07/07/20
- Fly Intel: Top five analyst downgrades
- 07/07/20 Wells Fargo
- First Hawaiian downgraded to Underweight from Equal Weight at Wells Fargo
- 07/07/20 Wells Fargo
- First Hawaiian downgraded to Underweight from Equal Weight at Wells Fargo
- 06/29/20 UBS
- First Hawaiian downgraded to Sell from Neutral at UBS
- 04/24/20
- First Hawaiian reports Q1 EPS 30c, consensus 38c
- 01/28/20
- First Hawaiian reports Q4 adj. EPS 54c, consensus 51c
- 05/11/20
- Eldorado Resorts reports Q1 adjusted EPS ($2.25) vs. 49c last year
- 02/26/20
- Eldorado Resorts reports Q4 EPS (17c), consensus 31c
- 02/26/20
- Notable companies reporting after market close
EBS Emergent BioSolutions - 04/30/20
- Emergent BioSolutions reports Q1 EPS (1c), consensus 1c
- 02/20/20
- Emergent BioSolutions sees FY20 revenue $1.175B-$1.275B, consensus $1.23B
- 02/20/20
- Emergent BioSolutions sees Q1 revenue $190M-$215M, consensus $262.06M
- 02/20/20
- Emergent BioSolutions reports Q4 EPS $1.57, consensus $1.73
- 05/11/20
- Caesars reports Q1 EPS (36c), consensus (18c)
- 05/11/20
- Notable companies reporting after market close
- 02/25/20
- Caesars reports Q4 EPS (45c), may not compare to consensus (11c)
- 02/25/20
- Notable companies reporting after market close
|
Hot Stocks
| ShowHide Related Items >><< - 04/24/20
- First Hawaiian suspends stock repurchase program
EBS Emergent BioSolutions - 07/20/20
- Emergent BioSolutions to replace Caesars in S&P 400 at open on 7/24
- 07/08/20
- Emergent BioSolutions enters collaboration with two others to evaluate COVID-HIG
- 07/06/20
- Emergent enters five-year agreement with Janssen for Ad26.COV2-S manufacturing
- 06/18/20
- Emergent BioSolutions investing $75M in Canton site expansion
- 07/07/20
- Fly Intel: Top five analyst downgrades
- 07/07/20 Wells Fargo
- First Hawaiian downgraded to Underweight from Equal Weight at Wells Fargo
- 07/07/20 Wells Fargo
- First Hawaiian downgraded to Underweight from Equal Weight at Wells Fargo
- 06/29/20 UBS
- First Hawaiian downgraded to Sell from Neutral at UBS
EBS Emergent BioSolutions - 07/17/20 Cantor Fitzgerald
- Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
- 07/02/20 Wells Fargo
- Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
- 06/26/20 Raymond James
- Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
- 06/08/20 Guggenheim
- Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
- 04/24/20
- First Hawaiian reports Q1 EPS 30c, consensus 38c
- 01/28/20
- First Hawaiian reports Q4 adj. EPS 54c, consensus 51c
EBS Emergent BioSolutions - 04/30/20
- Emergent BioSolutions reports Q1 EPS (1c), consensus 1c
- 02/20/20
- Emergent BioSolutions sees FY20 revenue $1.175B-$1.275B, consensus $1.23B
- 02/20/20
- Emergent BioSolutions sees Q1 revenue $190M-$215M, consensus $262.06M
- 02/20/20
- Emergent BioSolutions reports Q4 EPS $1.57, consensus $1.73
EBS Emergent BioSolutions - 06/08/20
- Fly Intel: Wall Street's top stories for Monday
- 06/08/20
- Fly Intel: Wall Street's top stories at midday
- 04/27/20
- Fly Insider: Accelerate Diagnostics, Abbott among week's notable insider trades
- 04/23/20
- Fly Intel: After-Hours Movers
|
Downgrade
|
Catch up on today's… Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kinder Morgan (KMI) downgraded to Sell from Neutral at Goldman Sachs with analyst Michael Lapides citing the stock's valuation and expects shares to lag large-cap midstream peers in the second half of 2020. 2. Cosan (CZZ) downgraded to Neutral from Overweight at JPMorgan with analyst Lucas Ferreira citing valuation. 3. Dominion (D) was downgraded to Neutral from Outperform at Credit Suisse and to Underperform from Neutral at Mizuho. 4. First Hawaiian (FHB) downgraded to Underweight from Equal Weight at Wells Fargo with analyst Jared Shaw saying the reality of the Hawaiian economy, among the hardest hit in the U.S. with a recovery expected to be the slowest, doesn't "square" with the current 30% TBV premium valuation. 5. Yeti (YETI) downgraded to Neutral from Buy at Goldman Sachs with analyst Alexandra Walvis saying the company's "strong" brand momentum and growth opportunity is now better understood by investors and reflected in the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. ShowHide Related Items >><< - 05/25/20
- Fly Intel: Top five weekend stock stories
- 04/17/20
- Yeti to replace LHC Group in S&P 600 at open on 4/17
- 04/14/20
- Yeti rises 13.2%
- 04/22/20
- Kinder Morgan raises annual dividend 5% to $1.05
- 03/08/20
- Fly Intel: Top five weekend stock stories
- 01/09/20
- Kinder Morgan announces sale of 25M shares of Pembina Pipeline
- 04/24/20
- First Hawaiian suspends stock repurchase program
- 07/06/20
- Dominion dividend cut 'not permanent'
- 07/06/20
- Dominion plans to spend 'tens of billions' on renewables
- 07/06/20
- Dominion: Sale of gas operations is 'right step at right time'
- 07/06/20
- Dominion: Sale of gas operations will enhance credit profile
- 03/09/20
- Cosan trading resumes
- 03/09/20
- Cosan trading halted, volatility trading pause
- 07/06/20 Goldman Sachs
- Kinder Morgan downgraded to Sell from Neutral at Goldman Sachs
- 05/18/20 BofA
- Plains All American, GP Holdings cut to Underperform at BofA
- 04/07/20 Mizuho
- Kinder Morgan price target lowered to $20 from $23 at Mizuho
- 03/24/20 Barclays
- Kinder Morgan upgraded to Overweight from Equal Weight at Barclays
- 07/07/20 JPMorgan
- Cosan downgraded to Neutral from Overweight at JPMorgan
- 05/27/20 HSBC
- Cosan downgraded to Hold from Buy at HSBC
- 05/20/20 Goldman Sachs
- Cosan downgraded to Neutral from Buy at Goldman Sachs
- 11/05/19 Bradesco BBI
- Cosan downgraded to Neutral from Outperform at Bradesco
- 07/07/20 Argus
- Dominion price target lowered to $80 from $87 at Argus
- 07/07/20 Mizuho
- Dominion downgraded to Underperform from Neutral at Mizuho
- 07/07/20 Credit Suisse
- Dominion downgraded to Neutral from Outperform at Credit Suisse
- 07/06/20 Wells Fargo
- Wells says merits of Dominion's 'forward-looking' deal to be clearer with time
- 07/07/20 Wells Fargo
- First Hawaiian downgraded to Underweight from Equal Weight at Wells Fargo
- 07/07/20 Wells Fargo
- First Hawaiian downgraded to Underweight from Equal Weight at Wells Fargo
- 06/29/20 UBS
- First Hawaiian downgraded to Sell from Neutral at UBS
- 06/29/20 UBS
- First Hawaiian downgraded to Sell from Neutral at UBS
- 07/07/20 Goldman Sachs
- Yeti downgraded to Neutral from Buy at Goldman Sachs
- 06/23/20 Piper Sandler
- Yeti price target raised to $47 from $35 at Piper Sandler
- 06/10/20 Cowen
- Yeti price target raised to $41 from $31 at Cowen
- 06/09/20 BTIG
- Yeti price target raised to $44 from $36 at BTIG
- 05/07/20
- Yeti withdraws 2020 guidance
- 02/13/20
- Yeti sees FY20 adjusted EPS $1.34-$1.39, consensus $1.37
- 02/13/20
- Yeti reports Q4 adjusted EPS 48c, consensus 43c
- 02/12/20
- Notable companies reporting before tomorrow's open
- 04/22/20
- Kinder Morgan sees FY20 adjusted EBITDA below plan by about 8%
- 04/22/20
- Kinder Morgan reports Q1 adjusted EPS 24c, consensus 27c
- 04/22/20
- Notable companies reporting after market close
- 01/22/20
- Kinder Morgan sees FY20 adjusted EBITDA roughly $7.6B
- 04/24/20
- First Hawaiian reports Q1 EPS 30c, consensus 38c
- 01/28/20
- First Hawaiian reports Q4 adj. EPS 54c, consensus 51c
- 07/06/20
- Dominion sees FY20 EPS ~$3.50, consensus $4.35
- 05/05/20
- Dominion backs FY20 EPS view of $4.25-$4.60, consensus $4.37
- 05/05/20
- Dominion sees Q2 EPS 75c-85c, consensus 92c
- 05/05/20
- Dominion reports Q1 EPS $1.09, consensus $1.10
|